(U.S. National Center for Infectious Diseases, 2006) Prosser, Lisa; Bridges, Carolyn Buxton; Uyeki, Timothy M.; Hinrichsen, Virginia L; Meltzer, Martin I.; Molinari, Noelle-Angelique M.; Schwartz, Benjamin; Thompson, William W.; Fukuda, Keiji; Lieu, Tracy
We estimated cost-effectiveness of annually vaccinating children not at high risk with inactivated influenza vaccine (IIV) to range from US $12,000 per quality-adjusted life year (QALY) saved for children ages 6–23 months to $119,000 per QALY saved for children ages 12–17 years. For children at high risk (preexisting medical conditions) ages 6–35 months, vaccination with IIV was cost saving. For children at high risk ages 3–17 years, vaccination cost $1,000–$10,000 per QALY. Among children not at high risk ages 5–17 years, live, attenuated influenza vaccine had a similar cost-effectiveness as IIV. Risk status was more important than age in determining the economic effects of annual vaccination, and vaccination was less cost-effective as the child's age increased. Thus, routine vaccination of all children is likely less cost-effective than vaccination of all children ages 6–23 months plus all other children at high risk.
